Toxic hepatitis due to a food supplement: “Natural” is no synonym for “harmless”

Clinics and Research in Hepatology and Gastroenterology

Volumn 40, Issue 4, 2016, Pages e38-e43

  Couturier, Filip J ^a,b   Colemont, Luc J ^a   Fierens, Herbert ^a   Verhoeven, Veronique M ^b  

^a Sint Vincentiusziekenhuis   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLINESTERASE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; IMMUNOGLOBULIN A; LACTATE DEHYDROGENASE;

AGED; ARTICLE; CASE REPORT; CHOLESTASIS; DIETARY SUPPLEMENT; DYSLIPIDEMIA; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LIVER BIOPSY; LIVER FUNCTION; PRIORITY JOURNAL; PROTHROMBIN TIME; TOXIC HEPATITIS; LIVER FUNCTION TEST; MALE;

AGED; CHEMICAL AND DRUG INDUCED LIVER INJURY; DIETARY SUPPLEMENTS; HUMANS; LIVER FUNCTION TESTS; MALE;

EID: 84959869243     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2015.12.016     Document Type: Article

References (29)

1. [1] European Association for Cardiovascular Prevention & Rehabilitation, Reiner, Z., Catapano, A.L., De Backer, G., Graham, I., Taskinen, M.R., et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32:14 (2011), 1769–1818.
2. [2] Chang, C.Y., Schiano, T.D., Review article: drug hepatotoxicity. Aliment Pharmacol Ther 25 (2007), 1135–1151.
3. [3] Ying Sing, S., T'ien Jung K'ai, W., Chinese technology in the seventeenth century. Sun E-T and Sun S-C, transl. 1966, Pennsylvania State University Press, London, 291–294.
4. [4] Khan, N., Mukhtar, H., Tea and health: studies in humans. Curr Pharm Des 19 (2013), 6141–6147.
5. [5] Hartley, L., et al. Green and black tea for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 6, 2013.
6. [6] Verhoeven, V., Lopez Hartmann, M., Remmen, R., Wens, J., Apers, S., Van Royen, P., Red yeast rice lowers cholesterol in physicians – a double blind, placebo-controlled randomized trial. BMC Complement Altern Med, 13, 2013, 178.
7. [7] Bogsrud, M.P., Ose, L., Langslet, G., Ottestad, I., Strøm, E.C., Hagve, T.A., et al. HypoCol (red yeast rice) lowers plasma cholesterol – a randomized placebo-controlled study. Scand Cardiovasc J 44 (2010), 197–200.
8. [8] Cicero, A.F., Derosa, G., Parini, A., Maffioli, P., D'Addato, S., Reggi, A., et al. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res 33 (2013), 622–628.
9. [9] Verhoeven, V., Van der Auwera, A., Van Gaal, L., Remmen, R., Apers, S., Stalpaert, M., et al. Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome? A double blind, placebo-controlled randomized trial. BMC Complement Altern Med, 15, 2015, 52.
10. [10] Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O.A., et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101 (2008), 1689–1693.
11. [11] Li, J.J., Lu, Z.L., Kou, W.R., Chen, Z., Wu, Y.F., Yu, X.H., et al. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol 49 (2009), 947–956.
12. [12] EFSA, Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J, 9, 2011, 2304 http://www.efsa.europa.eu/en/efsajournal/doc/2304.pdf accessed 21/07/2014.
13. [13] Venero, C.V., Venero, J.V., Wortham, D.C., Thompson, P.D., Lipid-lowering efficacy of red yeast rice in a population intolerant to statins. Am J Cardiol 105 (2010), 664–666.
14. [14] Becker, D.J., Gordon, R.Y., Halbert, S.C., French, B., Morris, P.B., Rader, D.J., Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med 150 (2009), 830–839 [W147–9].
15. [15] Lapi, F., Gallo, E., Bernasconi, S., Vietri, M., Menniti-Ippolito, F., Raschetti, R., et al. Myopathies associated with red yeast rice and liquorice: spontaneous reports from the Italian Surveillance System of Natural Health Products. Br J Clin Pharmacol 66 (2008), 572–574.
16. [16] Prasad, G.V., Wong, T., Meliton, G., Bhaloo, S., Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation 74 (2002), 1200–1201.
17. [17] Wigger-Alberti, W., Bauer, A., Hipler, U.C., Elsner, P., Anaphylaxis due to Monascus purpureus-fermented rice (red yeast rice). Allergy 54 (1999), 1330–1331.
18. [18] Grieco, A., Miele, L., Pompili, M., Biolato, M., Vecchio, F.M., Grattagliano, I., et al. Acute hepatitis caused by a natural lipid-lowering product: when “alternative” medicine is no “alternative” at all. J Hepatol 50 (2009), 1273–1277.
19. [19] Roselle, H., Ekatan, A., Tzeng, J., Sapienza, M., Kocher, J., Symptomatic hepatitis associated with the use of herbal red yeast rice. Ann Intern Med 149 (2008), 516–517.
20. [20] Pelli, N., Setti, M., Ceppa, P., Toncini, C., Indiveri, F., Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol 15 (2003), 921–924.
21. [21] Alla, V., Abraham, J., Siddiqui, J., Raina, D., Wu, G.Y., Chalasani, N.P., et al. Autoimmune hepatitis triggered by statins. J Clin Gastroenterol 40 (2006), 757–761.
22. [22] Vandenberg, B.F., Robinson, J., Management of the patient with statin intolerance. Curr Atheroscler Rep 12 (2010), 48–57.
23. [23] Sarma, D.N., Safety of green tea extracts: a systematic review by the US Pharmacopeia. Drug Saf 31 (2008), 469–484.
24. [24] Bonkovsky, H.L., Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med 144 (2006), 68–71.
25. [25] Yin, X., Yang, J., Li, T., Song, L., Han, T., Yang, M., et al. The effect of green tea intake on risk of liver disease: a meta analysis. Int J Clin Exp Med 8:6 (2015), 8339–8346.
26. [26] Li, Y.G., Zhang, F., Wang, Z.T., Hu, Z.B., Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal 35 (2004), 1101–1112.
27. [27] Hsin-Ping, O., Chiun, C.R.W., Lih-Shiuh, L., Thermal degradation kinetics analysis of monacolin K in Monascus-fermentated products LWT. Food Sci Technol 42 (2009), 292–296.
28. [28] Teschke, R., et al. Herbal hepatotoxicity: suspected cases assessed for alternative causes. Eur J Gastroenterol Hepatol 25 (2013), 1093–1098.
29. [29] Teschke, R., Frenzel, C., Schulze, J., Eickhoff, A., Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods. World J Gastroenterol 19:19 (2013), 2864–2882.